ZA200508427B - Methods for treating interleuking-6 related diseases - Google Patents

Methods for treating interleuking-6 related diseases

Info

Publication number
ZA200508427B
ZA200508427B ZA200508427A ZA200508427A ZA200508427B ZA 200508427 B ZA200508427 B ZA 200508427B ZA 200508427 A ZA200508427 A ZA 200508427A ZA 200508427 A ZA200508427 A ZA 200508427A ZA 200508427 B ZA200508427 B ZA 200508427B
Authority
ZA
South Africa
Prior art keywords
interleuking
treating
methods
related diseases
diseases
Prior art date
Application number
ZA200508427A
Other languages
English (en)
Inventor
Osamu Okuda
Noriaki Yoshida
Ravinder N Maini
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9957267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200508427(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of ZA200508427B publication Critical patent/ZA200508427B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA200508427A 2003-04-28 2005-10-18 Methods for treating interleuking-6 related diseases ZA200508427B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0309619A GB2401040A (en) 2003-04-28 2003-04-28 Method for treating interleukin-6 related diseases

Publications (1)

Publication Number Publication Date
ZA200508427B true ZA200508427B (en) 2006-08-30

Family

ID=9957267

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200508427A ZA200508427B (en) 2003-04-28 2005-10-18 Methods for treating interleuking-6 related diseases

Country Status (23)

Country Link
US (7) US7521052B2 (ja)
EP (5) EP3903819A1 (ja)
JP (9) JP4869063B2 (ja)
KR (4) KR101542336B1 (ja)
CN (4) CN105617387B (ja)
AR (1) AR044104A1 (ja)
AU (1) AU2004233700B2 (ja)
BR (1) BRPI0409910A (ja)
CA (2) CA2865872A1 (ja)
CL (2) CL2004000896A1 (ja)
CO (1) CO5700791A2 (ja)
GB (1) GB2401040A (ja)
HK (2) HK1096859A1 (ja)
IL (1) IL171285A (ja)
MX (1) MXPA05011266A (ja)
MY (1) MY146986A (ja)
NO (1) NO336061B1 (ja)
NZ (2) NZ567717A (ja)
RU (2) RU2509574C2 (ja)
TW (1) TWI400086B (ja)
UA (1) UA86587C2 (ja)
WO (1) WO2004096273A1 (ja)
ZA (1) ZA200508427B (ja)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CZ296979B6 (cs) * 1994-10-21 2006-08-16 Chugai Seiyaku Kabushiki Kaisha Farmaceutický prípravek pro prevenci nebo lécení Castlemanovy nemoci
EP2011514B1 (en) 1997-03-21 2012-02-29 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
PL201461B1 (pl) 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
NZ534542A (en) * 2002-02-14 2006-08-31 Chugai Pharmaceutical Co Ltd Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4651541B2 (ja) 2003-10-17 2011-03-16 中外製薬株式会社 中皮腫治療剤
AR048210A1 (es) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
JP4911894B2 (ja) * 2004-12-01 2012-04-04 アサマ化成株式会社 関節リウマチを予防するための経口投与用組成物
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP1941907B1 (en) * 2005-10-14 2016-03-23 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
AU2006305119B2 (en) * 2005-10-21 2012-12-20 Chugai Seiyaku Kabushiki Kaisha Agents for treating cardiopathy
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) * 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
WO2007116962A1 (ja) 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US20080015465A1 (en) * 2006-06-15 2008-01-17 Scuderi Gaetano J Methods for diagnosing and treating pain in the spinal cord
EA200900037A1 (ru) 2006-08-03 2009-10-30 Ваксинекс, Инк. Моноклональные антитела против интерлейкина-6 (il-6) и их применение
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
MX2009012493A (es) * 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados.
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
ES2610607T3 (es) 2007-05-21 2017-04-28 Alderbio Holdings Llc Anticuerpos contra IL-6 y usos de los mismos
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
CN101796197B (zh) 2007-06-08 2014-02-12 比奥根艾迪克Ma公司 预测抗tnf响应性或无响应性的生物标志物
WO2009014263A1 (ja) * 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
US8529895B2 (en) * 2007-10-02 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies
CN104888193A (zh) * 2007-11-07 2015-09-09 健泰科生物技术公司 用于治疗微生物病症的组合物和方法
CN101939424B (zh) 2007-12-05 2016-12-28 中外制药株式会社 抗nr10抗体及其应用
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
NO2708559T3 (ja) 2008-04-11 2018-08-25
CA2724279C (en) 2008-05-13 2017-03-07 Novimmune S.A. Anti-il-6/il-6r antibodies and methods of use thereof
JP5544290B2 (ja) * 2008-06-05 2014-07-09 独立行政法人国立がん研究センター 神経浸潤抑制剤
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
TW201041595A (en) 2009-05-15 2010-12-01 Chugai Pharmaceutical Co Ltd Anti-axl antibody
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
EP4406615A2 (en) 2009-10-26 2024-07-31 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
US9724410B2 (en) 2009-11-24 2017-08-08 Alderbio Holdings Llc Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
HUE060454T2 (hu) 2010-05-28 2023-03-28 Chugai Pharmaceutical Co Ltd Daganatellenes T-sejt-választ fokozó szer
CN104998254A (zh) 2010-11-08 2015-10-28 基因技术公司 皮下施用的抗-il-6受体抗体
BR112013012213A2 (pt) 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha moléculas de ligação a antígeno mul tlespecíficas tendo função alternativa à função dos fatores viii, ix e x de coagulação sanguínea, e anticorpo bies- 5 pecífico, seus usos na prevenção ou tratamento de hemorragia, ácido nucleico, vetor, célula, método para produzir as referidas moléculas de ligação, composição farmacêutica e kit
AU2011332817A1 (en) 2010-11-23 2013-06-13 Alder Biopharmaceuticals, Inc. Anti-IL-6 antibodies for the treatment of anemia
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
PL3326648T3 (pl) 2011-01-28 2021-10-11 Sanofi Biotechnology Kompozycje farmaceutyczne zawierające ludzkie przeciwciała przeciwko PCSK9
KR20200103845A (ko) 2011-02-25 2020-09-02 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
CN109432407A (zh) * 2011-03-11 2019-03-08 公共事业救济局-巴黎医院 低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9943594B2 (en) * 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
AU2013289967B2 (en) 2012-07-13 2018-03-29 The Children's Hospital Of Philadelphia Toxicity management for anti-tumor activity of CARs
US10822420B2 (en) * 2012-09-13 2020-11-03 Chugai Seiyaku Kabushiki Kaisha Gene knock-in non-human animal
KR102426481B1 (ko) 2013-03-15 2022-07-27 제넨테크, 인크. IL-22 폴리펩티드 및 IL-22 Fc 융합 단백질 및 사용 방법
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
MX363403B (es) 2013-07-04 2019-03-22 Hoffmann La Roche Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero.
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
CN104004059B (zh) * 2014-06-23 2016-03-30 周越 一种关于白介素-33抑制剂多肽及其应用
CN104004061B (zh) * 2014-06-23 2016-03-02 南通普悦生物医药有限公司 白介素-33抑制剂多肽及其应用
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SI3233921T1 (sl) 2014-12-19 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Protitelesa proti C5 in postopki za uporabo
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
PL3263132T3 (pl) 2015-02-27 2024-04-15 Chugai Seiyaku Kabushiki Kaisha Kompozycja do leczenia chorób związanych z il-6
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
RU2656160C2 (ru) * 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
AU2018234844B2 (en) 2017-03-17 2024-01-25 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
MX2020002750A (es) * 2017-09-13 2020-07-20 Jiangsu Hengrui Medicine Co Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
KR20200074160A (ko) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
WO2019177543A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
KR20210122810A (ko) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
AU2020290484A1 (en) 2019-06-12 2021-12-23 Regeneron Pharmaceuticals, Inc. Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis
CN111588850A (zh) * 2020-02-19 2020-08-28 中国科学技术大学 Il-6受体抗体的新用途

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55106216A (en) 1979-02-09 1980-08-14 Hitachi Chem Co Ltd Preparation of amino resin
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP2598666B2 (ja) * 1987-10-19 1997-04-09 忠三 岸本 抗ヒトｂｃｄｆモノクローナル抗体
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US6428979B1 (en) * 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5171840A (en) * 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5126250A (en) * 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2914672B2 (ja) 1989-01-17 1999-07-05 中外製薬株式会社 Ｂｓｆ▲下２▼アンタゴニスト
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
CA2021594C (en) 1989-07-20 2002-01-08 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
JPH03155795A (ja) 1989-11-13 1991-07-03 Chuzo Kishimoto マウス・インターロイキン―６レセプター蛋白質
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DK0628639T3 (da) * 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
JPH05227970A (ja) 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−６受容体に対する再構成ヒト抗体
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP4157160B2 (ja) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06319396A (ja) 1993-05-07 1994-11-22 Japan Tobacco Inc 抗ウイルス抗体を産生する植物及びその作出方法
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JPH07188056A (ja) 1993-07-21 1995-07-25 Chuzo Kishimoto インターロイキン６リセプター抗体を有効成分とする骨吸収抑制剤
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
JPH07324097A (ja) 1994-05-30 1995-12-12 Daicel Chem Ind Ltd インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
PL186506B1 (pl) 1994-10-07 2004-01-30 Chugai Pharmaceutical Co Ltd Sposób wytwarzania środka farmaceutycznego hamującego wzrost komórek błony maziowej i zastosowanie monoklonalnego przeciwciała
CZ296979B6 (cs) * 1994-10-21 2006-08-16 Chugai Seiyaku Kabushiki Kaisha Farmaceutický prípravek pro prevenci nebo lécení Castlemanovy nemoci
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
JP4079461B2 (ja) * 1994-12-29 2008-04-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを含んでなる抗腫瘍剤の作用増強剤
EP0811384B1 (en) * 1995-02-13 2006-06-21 Chugai Seiyaku Kabushiki Kaisha Muscle protein decomposition inhibitor containing il-6 receptor antibody
AU5332196A (en) 1995-03-31 1996-10-16 Henrik Georg Bohr Method for protein folding
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH08311098A (ja) 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
WO1997010338A1 (en) 1995-09-12 1997-03-20 Chiron Corporation Improved interleukin-6 receptor antagonist
IL130238A0 (en) * 1999-06-01 2000-06-01 Peptor Ltd Conformationally constrained backbone cyclized interleukin-6 antagonists
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
DE69735888T2 (de) * 1996-06-27 2006-11-02 Chugai Seiyaku K.K. Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoffsenfgasen verwendet werden kann
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
EP2011514B1 (en) * 1997-03-21 2012-02-29 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PL201461B1 (pl) * 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US7494652B1 (en) * 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
DE69934698T2 (de) 1998-08-24 2007-10-04 Chugai Seiyaku K.K. Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
JP3763698B2 (ja) * 1998-10-22 2006-04-05 株式会社日本自動車部品総合研究所 圧力脈動を緩和し得る燃料供給システムの設計方法
ES2234564T3 (es) * 1999-02-10 2005-07-01 Mitsubishi Pharma Corporation Compuestos de tipo amida y su uso en medicina.
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
US6413663B1 (en) 2000-06-29 2002-07-02 Graftech Inc. Fluid permeable flexible graphite fuel cell electrode
AU2001278716A1 (en) 2000-08-10 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Method of inhibiting antibody-containing solution from coagulating or becoming turbid
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DK1334731T3 (da) * 2000-10-25 2008-05-26 Chugai Pharmaceutical Co Ltd Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
WO2002036164A1 (fr) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent abaissant le taux sanguin de vegf contenant un antagoniste de il-6 en tant que principe actif
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
EP3088412B1 (en) * 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1382964A4 (en) 2001-04-17 2009-06-10 Chugai Pharmaceutical Co Ltd METHOD FOR TENSID QUANTIFICATION
MXPA04004671A (es) * 2001-11-14 2005-08-25 Johnson & Johnson Anticuerpos anti-interleucina-6, composiciones, metodos y usos.
NZ534542A (en) 2002-02-14 2006-08-31 Chugai Pharmaceutical Co Ltd Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
DK2261230T3 (en) 2002-09-11 2017-06-12 Chugai Pharmaceutical Co Ltd Method of Protein Purification.
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
WO2004073741A1 (ja) * 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CA2519408C (en) 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4651541B2 (ja) * 2003-10-17 2011-03-16 中外製薬株式会社 中皮腫治療剤
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
AR048335A1 (es) * 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
CA2593521C (en) * 2005-01-05 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Cell culture method and utilization of the same
EP1941907B1 (en) * 2005-10-14 2016-03-23 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
AU2006305119B2 (en) * 2005-10-21 2012-12-20 Chugai Seiyaku Kabushiki Kaisha Agents for treating cardiopathy
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) * 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
EP3135298B1 (en) * 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
US20090061466A1 (en) * 2006-03-09 2009-03-05 Wolfgang Hoesel Anti-drug antibody assay
WO2007116962A1 (ja) * 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
WO2008016134A1 (fr) 2006-08-04 2008-02-07 Norihiro Nishimoto PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
US9725514B2 (en) * 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
US8529895B2 (en) * 2007-10-02 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
WO2009077127A1 (en) * 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Distinguishing assay
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP5544290B2 (ja) * 2008-06-05 2014-07-09 独立行政法人国立がん研究センター 神経浸潤抑制剤
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
MY161541A (en) * 2009-07-31 2017-04-28 Shin Maeda Cancer metastasis inhibitor
EP4406615A2 (en) 2009-10-26 2024-07-31 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
WO2011128096A1 (en) * 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
HUE060454T2 (hu) 2010-05-28 2023-03-28 Chugai Pharmaceutical Co Ltd Daganatellenes T-sejt-választ fokozó szer
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
WO2011154139A2 (en) * 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
US9422329B2 (en) 2010-11-05 2016-08-23 Hoffmann-La Roche Inc. Optimized method for antibody capturing by mixed mode chromatography
CN104998254A (zh) 2010-11-08 2015-10-28 基因技术公司 皮下施用的抗-il-6受体抗体
BR112014004828B8 (pt) 2011-09-01 2022-03-29 Chugai Pharmaceutical Co Ltd Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração
MX363403B (es) 2013-07-04 2019-03-22 Hoffmann La Roche Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero.
PL3263132T3 (pl) 2015-02-27 2024-04-15 Chugai Seiyaku Kabushiki Kaisha Kompozycja do leczenia chorób związanych z il-6
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados

Also Published As

Publication number Publication date
JP2024023876A (ja) 2024-02-21
JP2011126910A (ja) 2011-06-30
KR20140099948A (ko) 2014-08-13
NO20054959L (no) 2006-01-19
RU2009105062A (ru) 2010-08-20
US20150010554A1 (en) 2015-01-08
EP2368577A2 (en) 2011-09-28
CA2523577A1 (en) 2004-11-11
US10744201B2 (en) 2020-08-18
US7521052B2 (en) 2009-04-21
WO2004096273A1 (en) 2004-11-11
JP2016014065A (ja) 2016-01-28
US8709409B2 (en) 2014-04-29
JP2019011372A (ja) 2019-01-24
CA2523577C (en) 2018-04-03
CN111068062B (zh) 2022-07-19
HK1096859A1 (en) 2007-06-15
EP4098279A1 (en) 2022-12-07
JP2020172493A (ja) 2020-10-22
MXPA05011266A (es) 2006-01-24
CL2008002207A1 (es) 2009-01-02
UA86587C2 (ru) 2009-05-12
JP4869063B2 (ja) 2012-02-01
MY146986A (en) 2012-10-15
BRPI0409910A (pt) 2006-04-25
NO336061B1 (no) 2015-05-04
US20210283250A1 (en) 2021-09-16
US20190054167A1 (en) 2019-02-21
EP2368577A3 (en) 2012-03-14
CN1849135A (zh) 2006-10-18
JP2014031388A (ja) 2014-02-20
US20060251653A1 (en) 2006-11-09
KR101385822B1 (ko) 2014-04-16
US20090181029A1 (en) 2009-07-16
US20140017236A1 (en) 2014-01-16
CN105617387B (zh) 2021-09-14
RU2509574C2 (ru) 2014-03-20
JP2022066460A (ja) 2022-04-28
CA2865872A1 (en) 2004-11-11
US20210170024A1 (en) 2021-06-10
EP3167901A1 (en) 2017-05-17
KR101542336B1 (ko) 2015-08-25
CO5700791A2 (es) 2006-11-30
NO20054959D0 (no) 2005-10-25
TWI400086B (zh) 2013-07-01
IL171285A (en) 2016-02-29
NZ543073A (en) 2008-06-30
CN1849135B (zh) 2011-06-15
CN111068062A (zh) 2020-04-28
EP1617869A1 (en) 2006-01-25
KR20060010765A (ko) 2006-02-02
GB2401040A (en) 2004-11-03
JP2006524685A (ja) 2006-11-02
AR044104A1 (es) 2005-08-24
JP5881667B2 (ja) 2016-03-09
EP3903819A1 (en) 2021-11-03
KR20090051126A (ko) 2009-05-20
AU2004233700A1 (en) 2004-11-11
GB0309619D0 (en) 2003-06-04
KR20130030822A (ko) 2013-03-27
CL2004000896A1 (es) 2005-03-28
CN102172403A (zh) 2011-09-07
JP5777361B2 (ja) 2015-09-09
HK1219678A1 (zh) 2017-04-13
JP2016222740A (ja) 2016-12-28
AU2004233700B2 (en) 2010-03-04
RU2367471C2 (ru) 2009-09-20
CN105617387A (zh) 2016-06-01
RU2005136881A (ru) 2007-06-10
TW200507849A (en) 2005-03-01
NZ567717A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
ZA200508427B (en) Methods for treating interleuking-6 related diseases
IL175818A0 (en) Method for treating adamts-5- associated disease
EP1636359A4 (en) METHODS OF TREATING PAIN
PL1655036T3 (pl) Sposób leczenia chorób onkologicznych
EP1696877A4 (en) PROCESS FOR PAIN TREATMENT
PL1706112T3 (pl) Sposoby leczenia chorób związanych z zapaleniem
EP1613308A4 (en) CANCER TREATMENT METHODS
EP1635763A4 (en) METHOD FOR TREATING NEURODEEGENERATIVE ILLNESSES
EP1689485A4 (en) CARDIOELECTROMAGNETIC TREATMENT
HK1102106A1 (en) Method for treating intraocular neovascular diseases
EP1622609A4 (en) METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
IL164352A0 (en) Methods for treating tweak-related conditions
EP1755394A4 (en) METHOD OF TREATING CANCER
EP1677816A4 (en) THERAPEUTIC METHOD
EP1765344A4 (en) CANCER TREATMENT METHOD
HK1092180A1 (en) Methods for treating ischemic diseases
GB0312407D0 (en) Treatment
EP1809276A4 (en) PROCESSING PROCESS
EP1768963A4 (en) CANCER TREATMENT METHOD
EP1802617A4 (en) CANCER TREATMENT METHOD
IL210418A0 (en) Peptides for treating amyloid - associated diseases
GB0307544D0 (en) Treatment method
GB0312122D0 (en) Therapeutic method
GB0302691D0 (en) Treatment method
AU2003300471A8 (en) Methods for treating ocular diseases